Market Signal Briefing

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Former New York City Mayor Eric Adams has reportedly entered the crypto scene with the bold launch of a meme coin. The meme coin, called the NYC Token, is introduced with a key focus on fighting rising anti-American sentiment and antisemitism. Adams noted that the revenue raised will also be used to educate children on blockchain and other innovative technologies.

Eric Adam’s meme coin has now become a strong competitor to political-themed tokens like TRUMP and MELANIA. The NYC Token launch marks the latest entry in the growing intersection of politics and crypto, with the meme coin news sparking interest from investors and media.

Meme Coin News: Eric Adams Launches NYC Token According to the latest reports, New York City’s former Mayor Eric Adams has launched his own meme coin, called NYC Token. Rather than just a money-making token, Adams sees this meme coin as a “commemorative asset,” highlighting its key focus on social causes.

Adams unveiled the meme coin project on Monday at a Times Square press event. He addressed the token as a cryptocurrency project with a civic focus. As per his statement, the token intends to combat anti-American sentiment and antisemitism, as well as provide blockchain education.

Reportedly, the NYC token boasts a total supply of one billion coins. Of this, 80 million is available for trading at launch. Soon, the circulation will be expanded to 300 million. The project’s goals include supporting youth’s crypto education, providing scholarships for underserved students, and more. However, key details, like the project’s partners and its whitepaper, are missing on the official website. This prompts critics to question its transparency and ethical foundations.

Liquidity Concerns Spark Rug Pull Accusations Shortly after the debut, the NYC token surged to a staggering market capitalization of $580 million. This reflects the growing demand for the token from retail investors and market participants.

Soon, the Solana-based meme coin plunged by more than 80%, with the market cap reaching $90 million after hitting $730 million. However, it later managed to recover above $110 million.

The New York Mayor’s meme coin project soon experienced major liquidity shifts, sparking concerns about the token’s structure and management. According to analytics firm Bubblemaps, a wallet connected to the NYC Token’s deployer has withdrawn about $2.5 million in USDC liquidity near the token’s peak value. Nearly $1.5 million was later returned when the price fell by about 60%.

As reported by the researchers, Wallet 9Ty4M created a one-sided liquidity pool on Meteora, removed $2.5 million, and moved back $1.5 million following the declines. These actions indicate a possible rug pull.

Political Meme Coins: From Trump and Melania to NYC Token Interestingly, the NYC Token is now one among the politically linked meme coins, along with Donald Trump’s TRUMP and Melania Trump’s MELANIA. These politically linked meme coins often combine celebrity influence with crypto speculation. They attract both political supporters and investors.

The NYC Token launch reportedly coincides with the alleged death of the TRUMP Coin. TRUMP has been facing a sustained downward trend over the past few weeks, currently trading at $5.39.

In contrast, the MELANIA crypto is currently facing renewed positivity, with the token price jumping by 10% in a day. Over the past week and month, MELANI has surged by 24% and 54% respectively.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Monero (XMR) has continued with its performance as it reclaims its position as the leading privacy currency over Zcash. This happened only after a day when the UAE banned this type of currency from being part of their financial market.

Monero Surges As UAE Makes Privacy Coin Illegal The XMR token has taken its place as the most highly valued privacy coin after its price rallied explosively to set a new all-time high in the market. This is despite the announcement of the ban of privacy tokens in Dubai only some hours ago.

Source: TradingView; XMR Price Daily Chart According to market intelligence service Santiment, the token rose over 44% over a week and a half, even reaching a peak just shy of $657. The data service observed that even though the token has strong momentum, traders should be tracking social market data.

📈 Monero's +44% surge over the past 8 days led to a $608 all-time high. If you are looking for an entry point, consider doing so after social hype and FOMO wears off slightly. The privacy sector has been a breath of fresh air these past 3 months, with $XMR now in the forefront… pic.twitter.com/fsmS0u9dlr

— Santiment (@santimentfeed) January 12, 2026

They shared that privacy-based assets have been performing better than the entire crypto market over the last three months. Monero stood out as the top asset while others slowed down.

In contrast, the Zcash token saw a decline after the departure of its core development team due to a disagreement with its board. This created some doubt about the future upgrade of the token. Thus, the token dropped by about 15% in a single day, negating some of the progress made.

According to analysts, the rally followed an extended period of accumulation when prices gradually increased while major cryptocurrencies were finding themselves in tight ranges.

Technically, the asset has broken above the multiyear resistance level that previously limited the incremental progress since the last cycle in the financial markets. The momentum indicators are currently reflecting the kind of environment seen during the previous phases of expansion.

It means the current trend could continue, provided the Monero price remains above the resistance level. Various market research firms have pointed towards the growing global requirement for financial privacy as another key trend that the new year will witness leading up to 2026.

Peter Brandt Compares XMR to Silver Respected trader Peter Brandt compared the token’s structure to a historical silver breakout. According to his analysis, both of these markets created two peaks over a period of time. Ultimately, silver broke above that level and created an expansion candle that started the beginning of a major move.

Source: X Although Brandt did not put forth a concrete target price for Monero, the analogy implies that perhaps the early stages of this type of structural breakout could still be underway.

Even with a new record price, the dominance strength is considered relatively small compared to the previous cycle peaks. This is seen as a sign that there is room for growth.

Tue, 13/01/2026 - 7:41

In his new statement, Bitmine's Tom Lee shares incredibly ambitious goals and big milestones for his Ethereum DAT.

Cover image via u.today Bitmine Immersion (BMNR) now holds over 3.45% of the total Ethereum (ETH) supply, with 5% being the nearest future target. The platform is also ready to become the largest ETH staking machine in 2026.

Bitmine holdings now total $14 billion, Tom Lee saysAccording to the official statement by Tom Lee, CEO of Ethereum DAT Bitmine (BMNR), the company's total assets now exceed $14 billion. This massive sum includes both crypto and cash holdings in its portfolio.

🧵🪡
BitMine shareholders, please read this thread carefully. It is about the upcoming shareholder vote and why we need every shareholder to participate:

➡️ this company's charter is unusual
➡️ and needs 50.1% of outstanding shares to vote YES
➡️ to increase authorized shares…

HOT Stories

— Bitmine (NYSE-BMNR) $ETH (@BitMNR) January 9, 2026 The company's crypto holdings are comprised of 4,167,768 ETH at $3,119 per ETH, 193 Bitcoin (BTC), a $23 million stake in Eightco Holdings (NASDAQ: ORBS) ("moonshots") and total cash of $988 million. 

As such, Bitmine's ETH holdings are new responsible for 3.45% of the ETH supply (of 120.7 million ETH).

Despite general market pessimism, Thomas "Tom" Lee of Fundstrat, Chairman of Bitmine, is sure that 2026 will be the big year for his company and the entire ETH ecosystem:

2026 augurs many positive things for crypto with stablecoin adoption and tokenization driving to make blockchain the settlement layer of Wall Street, particularly favoring Ethereum. We continue to view the leverage reset post October 10th, 2025 as akin to the 'mini crypto winter.' 2026 is the year crypto prices recover and with stronger gains in 2027-2028

Also, Tom Lee stressed that Bitmine remains the most active Ethereum (ETH) buyer of all "fresh money" companies on the market.

Bitmine has ambitions to become the largest ETH staking operator in 2026Also, Lee highlights that Bitmine is nearing the launch of MAVAN, its own ETH staking business. Once it is live, it has a great chance to become the largest Ethereum (ETH) staking operator.

As of Jan. 11, 2026, Bitmine total staked ETH stands at 1,256,083. Bitmine is currently working with two leading staking providers to find a perfect technical solution.

As of January 2026, ETH staking rewards sit between 2.8% and 3.5% annually.

Related articles

XRP edged modestly higher to around $2.06, managing to hold above short-term support after a choppy trading session that reflected broader indecision across the crypto market. A brief late-session burst of buying activity helped lift prices off intraday lows, but overall conviction remained muted as traders continued to wait for a clearer directional trigger. The price action in XRP closely mirrored the wider market, where major cryptocurrencies like bitcoin and ether struggled to extend recent rallies during U.S. trading hours, reinforcing a “sell-the-rally” environment that capped risk appetite.

The lack of fresh, XRP-specific news kept sentiment neutral. While longer-term factors such as ETF-related optimism, institutional positioning, and network activity continue to provide a supportive backdrop, none were strong enough on the day to push XRP decisively out of its established multi-week trading range. As a result, traders focused primarily on short-term technical levels, especially as liquidity thinned and correlation with the broader crypto market remained high.

Over the past 24 hours, XRP traded within a relatively tight range between approximately $2.04 and $2.11. Multiple attempts to break above the $2.09–$2.11 area were quickly rejected, reinforcing that zone as a key resistance level where selling pressure remains active. On the downside, buyers consistently stepped in around the $2.04–$2.05 region, establishing it as a well-defended support area and helping contain downside risk.

Trading volume stayed close to average for most of the session, highlighting the absence of aggressive participation from larger market players. However, activity picked up briefly in the final hour, when a sharp increase in buying volume pushed XRP from near $2.05 to around $2.07. The move held, but momentum faded quickly, suggesting short-term positioning rather than a meaningful shift in trend.

Overall, XRP’s structure continues to point to consolidation rather than distribution. Price remains compressed between rising short-term support and descending resistance, a technical setup that often precedes a more pronounced move once volume and participation expand. As long as XRP holds above the $2.04–$2.05 zone, the market remains balanced with a slight upward bias. A sustained breakout above $2.10–$2.11 could open the door to a push toward the mid-$2.20s, while a clean break below support would shift attention back to the $1.90–$2.00 demand area. For now, XRP appears to be a market waiting for its next catalyst.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Bitcoin (BTC) and ether (ETH) traders are increasingly positioning for a quieter market, looking past major catalysts such as geopolitical tensions, ETF flows, and macroeconomic uncertainty. This shift in sentiment is clearly reflected in the sharp decline in 30-day implied volatility (IV) for both leading cryptocurrencies, suggesting expectations of reduced short-term risk and fewer dramatic price swings.

Bitcoin’s annualized 30-day implied volatility, tracked by Deribit’s DVOL index, has fallen to around 40%, marking its lowest level since October. This is a significant drop from the November peak near 59%, recorded during a period of heightened market stress. Volmex’s Bitcoin Volatility Index (BVIV) confirms a similar downward trend, reinforcing the view that traders are bracing for consolidation rather than sharp directional moves.

Ether has followed a comparable path. ETH’s DVOL index has slipped below 60%, its lowest level since September 2024, after topping out above 80% during November’s volatility spike. The easing volatility indicates that traders are stepping back from aggressive hedging strategies and reducing demand for near-term options protection.

Options market activity supports this narrative. Recent trading on Deribit shows a concentration of both call and put selling, a strategy typically used to profit from declining volatility. This behavior suggests that market participants expect prices to remain range-bound rather than break out sharply in either direction. According to market analysts, traders are unwinding hedges and supplying volatility, reflecting confidence that near-term uncertainty is fading.

The relative risk perception between ether and bitcoin is also shifting. The spread between ETH and BTC 30-day implied volatility has narrowed to around 16, the lowest since April 2025, down sharply from levels above 30 seen last August. This indicates that traders are unwinding Ethereum-related risk faster than Bitcoin risk, although ETH is still expected to be slightly more volatile than BTC.

Overall, despite lingering concerns such as weak U.S. spot Bitcoin ETF demand and a strong dollar, crypto options markets are signaling a period of calmer trading ahead, with both bitcoin and ether expected to cool off in the near term.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Journalist

Posted: January 13, 2026

The ETF game has moved beyond the “new player” narrative in the blockchain space, with institutions increasingly investing in memecoins. The previous year was characterized by a couple of approvals that included major altcoins.

However, the start of this year appears to have been uneventful.

SEC delays decision on Grayscale’s PENGU ETF  The U.S. Securities and Exchange Commission delayed its decision on Grayscale’s Pudgy Penguins [PENGU] ETF until the 11th of March.

The extension granted the Commission an additional 60 days to review the proposed rule change, according to the filing.

That delay followed the SEC’s initiation of proceedings in September 2025, pushing the final deadline beyond the original January timeline.

From a sentiment perspective, such delays often weighed on short-term price action. The decision also affected broader crypto ETF proposals, including T. Rowe Price’s multi-asset filing.

While that appears to be bearish, smart money is taking advantage of the silence in the memecoin.

This could negate this outlook, flipping the market to bullish now that the memecoin market has been the best performer since the start of the year.

Institutions buy more but volume cools off On that note, institutions have been on a buying spree over the past month. In fact, Digital Finance Group added more than 21.2 million PENGU over the last 30 days.

This smart money addition meant the institution joined other active funds in the accumulation process. Sigil Fund held 45.5 million tokens valued at $557K, while Moonrock Capital had $33.7K PENGU.

Source: Nansen AI

That was not the end of smart money involvement, as DevmonsGG added 6.7 million PENGU tokens.

Despite this massive buying by institutions, the volume cooled off from a high of $14 million to around $5 million. This explained the reason behind the accumulation, as big players like to act when the market is weak.

How is PENGU’s price action affected? The price action was a reflection of the ETF delay and volume decline. PENGU’s price was ranging around $0.01166, but its mindshare was exploding.

The strong green candle that emerged on the 4-hour chart was a sign of a breakout. To back this up, the MACD had been red but now had printed the first bullish bar.

Source: TradingView

The delayed decision by the SEC may have derailed the price breakout. Alternatively, it could be a market-wide correction after the rally in the first week of January.

A break above $0.01300 could fuel the price toward $0.013779, whose eventual breach would shift the current outlook.

Final Thoughts Regulatory delays often test market patience, but they do not always dictate institutional behavior. In PENGU’s case, steady accumulation during low-volume conditions suggested longer-term positioning rather than short-term reaction. Whether that conviction translates into follow-through may depend on how the price responds once regulatory clarity returns.

SHIB price crashes below key levels as 140 trillion tokens turn unprofitable. On-chain data reveals massive exchange inflows signaling further downside for Shiba Inu holders.

Newton Gitonga2 min read

13 January 2026, 08:07 AM

Shiba Inu has experienced a severe price correction over the past week. The meme coin erased most of its recent gains, triggering widespread selling among holders. SHIB currently trades at $0.00000842, down 2.74% from its position seven days ago.

The decline marks a stark reversal from early January optimism. On-chain metrics reveal the extent of damage to investor positions. At the start of 2025, approximately 140 trillion SHIB tokens were held in profit. This figure reflected strong sentiment following December's rally when the token briefly touched $0.00001000 on December 5.

That bullish momentum collapsed quickly. Within just one week, the supply in profit plummeted by 62%. Only 57 trillion SHIB tokens now remain profitable. The rapid contraction demonstrates how swiftly market conditions shifted against holders.

Shiba Inu Supply In Profit, Source: Glassnode

Exchange Inflows Signal Distribution PhaseOn-chain data points to a fundamental change in market dynamics. Exchange net position indicators show persistent green bars throughout the recent decline. These signals indicate tokens are flowing into exchanges rather than moving to cold storage.

Rising exchange balances typically precede further price weakness. Tokens deposited on exchanges sit closer to potential sale execution. The pattern suggests holders are positioning for exits rather than accumulation.

This behavior creates a self-reinforcing cycle. Declining profitability prompts selling decisions. Increased supply on exchanges adds downward pressure. Without fresh demand, the structure favors continued weakness.

The shift from accumulation to distribution appears decisive. December saw retail participation increase as SHIB rallied. That engagement has reversed as losses mounted. Many holders who entered during the spike now face underwater positions.

Critical Support Level Under ThreatSHIB trades just above a crucial support zone at $0.00000836. This level coincides with the 50-day exponential moving average. A break below would confirm technical deterioration and likely trigger additional selling.

The next support target sits at $0.00000786 if current levels fail. Such a move would deepen the correction by an additional 8% from current prices. Technical indicators suggest momentum remains negative.

Source, TradingView

However, a recovery scenario exists if buyers defend the $0.00000836 floor. A successful bounce could drive prices toward $0.00000898 resistance. Clearing that barrier would flip the 100-day EMA into a support role and stabilize the trend.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Newton Gitonga covers cryptocurrencies, blockchain, and digital finance. He specializes in breaking down complex trends with clear, data-driven reporting. His work focuses on market analysis, technical insights, and the evolving role of altcoins in shaping global markets.

Read more about

Latest Shiba Inu News Today (SHIB)

Shiba Inu (SHIB) entered 2026 with mixed momentum as fresh on-chain signals paint a nuanced short-term outlook for the memcoin favorite. 

After kicking off the year with a modest rebound from deep consolidation, Shiba Inu price has lost its recent gains and slipped back toward the key support zone of $0.000008300 around the 20 day EMA zone.

At press time, SHIB trades around $0.000008560, displaying muted performance in the past 24 hours.

SHIB Price Outlook: Consolidation With Potential for BreakoutIn the past few sessions, Shiba Inu price has showcased retracement and stays close to the 20 day EMA zone around $0.000008560. Amidst low trading volume support, SHIB has struggled to maintain upward momentum despite brief recovery attempts.

Following a rebound from the recent lows of $0.00000680-$0.00000720 zone, the memecoin has failed to extend the gains and displayed range bound moves. 

The zone around $0.00000800- $0.00000900 has emerged as a congestion zone, with buyers defending dips but lacking the strength to push price decisively higher.

Meanwhile, SHIB price continues to face resistance near $0.00000900-$0.00000980, a zone that has repeatedly capped upside moves. 

On the downside, support around $0.00000750-$0.00000800 remains crucial. A break below this floor could expose SHIB to deeper corrections, while a clean move above resistance may trigger short-term bullish momentum.

While the momentum indicators outlook remains mixed. The Relative Strength Index (RSI) hovers near the neutral mark, showing neither overbought nor oversold conditions. 

Moreover, the ADX suggests consolidation rather than a clear trend, reinforcing the idea that SHIB is in a “wait-and-watch” phase for traders.

Whale Activity and Exchange Supply Send Mixed SignalsBesides the technicals, SHIB’s on-chain data is painting an interesting picture. Large holder activity has surged sharply, with whale transactions rising, indicating that the big players are controlling the liquidity.

According to TKResearch Trading, whales appear to be controlling SHIB's exchange liquidity. Since December 5, exchanges have recorded a net outflow of 80 trillion SHIB, with exchange balances declining from 370.3 trillion to 290.3 trillion. In the past 60 days, certain new… pic.twitter.com/ZNv8LwBBmY

— Wu Blockchain (@WuBlockchain) January 12, 2026 In parallel, notable SHIB withdrawals from centralized exchanges suggest some investors are moving tokens into long-term storage.

Adding to this, the exchange reserves have shown a gradual decline, a signal often associated with reduced immediate sell pressure. 

When fewer tokens sit on exchanges, the available supply for sudden sell-offs tightens. This shows a structurally positive sign over time.

What Comes Next For SHIB?In the short-term, SHIB appears locked in consolidation,with whale accumulation and declining exchange supply providing a supportive backdrop, but price confirmation is still missing. A sustained breakout above the resistance zone of $0.00000900-$0.00000100 could trigger a positive sentiment in favor of bulls.

Until then, SHIB is likely to move sideways, with volatility building beneath the surface.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Toronto, Ontario--(Newsfile Corp. - January 13, 2026) - Tsodilo Resources Limited (TSXV: TSD) (OTCQB: TSDRF) (FSE: TZO) ("Tsodilo" or the "Company") is pleased to announce the verification of significant critical minerals and rare earth element ("REE") mineralization from its 100%-owned Gcwihaba Metals Project ("Gcwihaba" or the "Project"), located in northwest Botswana. The C26 and C27 targets were initially identified as geophysical anomalies through ground magnetic and gravity surveys. Diamond core drilling of these anomalies confirmed skarn-hosted REE mineralization 20-50 meters below surface. The skarns and other project area proximate targets contain a polymetallic assemblage including fifteen rare earth elements and critical minerals such as copper, cobalt, nickel, vanadium, and silver.

MAJOR HIGHLIGHTS

C26 and C27 Skarn features contains 15 of the 15 REE elements listed on the U.S. Department of Interior, U.S. Geological Survey's 2025 list of Critical Minerals and 5 other critical minerals as well.C26 and C27 skarn Neodymium-praseodymium (NdPr) content represents approximately 15% of Total Rare Earth Oxides (TREO) comparable to MP Materials' Mountain Pass mine (15.7%). NdPr is essential for high-performance permanent magnet applications in electric vehicles, wind turbines, and defense systems.15,000m drill program will commence in 2026 to obtain a compliant NI43-101 resource statement. Based on integrated geophysical modelling, drilling results, and geological modelling of the confirmed skarn deposits, the Company has defined a conceptual exploration target ranging from 81 to 97 million tonnes at grades between 0.05% and 1.49% TREO. The REE exploration target measures four kilometers in length.

Figure 1a – Total REE concentrations map across Gcwihaba Metals Project and Figure 1b – Location Map - C26 & C27 Skarn

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11216/280123_figure1.jpg

Tsodilo's Chairman and CEO, James M. Bruchs, comments:

"The 1.49% TREO intercept at C27 represents the highest grade recorded so far for Gcwihaba," stated James M. Bruchs, Chairman and CEO. "These results validate our systematic exploration approach and demonstrate evidence of a polymetallic REE skarn system with both vertical extent and grade. Our conceptual exploration target of 81 to 97 million tonnes was generated through integrated magnetic and gravity geophysical modelling using a ground magnetics inversion model, constrained by drilling results and geological interpretation. This modelling was completed in-house using Paradigm GOCAD software. Beyond rare earth elements, the skarn system has returned encouraging base and precious metal values, including copper up to 0.41% in the C26 skarn, cobalt up to 320 ppm, and silver up to 5.1 g/t in the C27 skarn. The 2026 drilling program will focus on defining high-grade REE zones while further evaluating the polymetallic potential of the system to support preparation of an initial mineral resource estimate."

Rare earth elements are used in permanent magnets for electric vehicles, wind turbines, and defense technologies. Global supply is concentrated in China, with demand projected to grow at 9.2% annually through 2030. Rare earth elements and cobalt are included in the US Department of the Interior Critical Minerals List ("CML"). The C26 and C27 skarns mineralization contain all fifteen rare earth elements on the 2025 US Department of the Interior Critical Minerals List ("CML"), including neodymium and praseodymium, plus five additional CML minerals including cobalt, copper, nickel, vanadium, and silver. In total, 20 of 60 CML minerals have been identified.

Figure 2: Gcwihaba Skarn Metals Project Critical Minerals & Rare Earth Elements

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11216/280123_f7c6ad0b24ca3954_011full.jpg

This represents the first systematic assessment of REE potential at the Gcwihaba Metals Project. The Company has completed twelve NQ-size exploration drill holes (totaling 3,303 meters) to date across the C26 and C27 skarn targets. A total of 1,612 diamond core samples from nine drill holes were analyzed for multi-element geochemistry, with 1,224 samples (76%) returning detectable REE mineralization. Four drill holes returned high-grade REE intercepts up to 1.49% TREO at the C27 skarn anomaly.

Drill Results

C27 Skarn Anomaly:

1.49% TREO over 2m (159.5-161.5m) in Hole 1822C27_61.23% TREO over 1m (146.4-147.4m) in Hole 1822C27_245m @ ≥0.1% TREO (74.4-243.4m) in Hole 1822C27_2C26 Skarn Anomaly:

18m @ ≥0.1% TREO (77.6-190.6m) in Hole 1822C26_14m @ ≥0.1% TREO (103.4-111.4m) in Hole 1822C26_3C27 Skarn deposit returned 1.49% TREO over 2m (159.5-161.5m) including 984 ppm Nd, 388 ppm Pr, 92 ppm Cu, 36 ppm Co, and 1.1 g/t Ag in Hole 1822C27_6. 1.23% TREO over 1m (146.4-147.4m) including 1,195 ppm Nd, 438 ppm Pr, 430 ppm Cu, 71 ppm Co, and 0.2 g/t Ag in Hole 1822C27_2. 45m @ ≥0.1% TREO (74.4-243.4m) averaging 0.29% TREO, 330 ppm Nd, 123 ppm Pr, 517 ppm Cu, 75 ppm Co, and 0.7 g/t Ag in Hole 1822C27_2.

C26 Skarn deposit returned 18m @ ≥0.1% TREO (77.6-190.6m) averaging 0.16% TREO, 214 ppm Nd, 63 ppm Pr, 733 ppm Cu, and 1.0 g/t Ag in Hole 1822C26_1. 0.46% TREO over 1m (172.6-173.6m) including 473 ppm Nd, 154 ppm Pr, 927 ppm Cu, and 1.0 g/t Ag in Hole 1822C26_1. 4m @ ≥0.1% TREO (103.4-111.4m) averaging 0.23% TREO, 258 ppm Nd, 82 ppm Pr, 288 ppm Cu, and 1.0 g/t Ag in Hole 1822C26_3. The Company plans to commence further diamond core drilling on the C27 and C26 skarn deposits in 2026.

Table 1: Rare Earth Elements, Copper, Cobalt & Silver Drill Results Summary - Gcwihaba Project

TargetPeak GradePeak
Nd
(ppm)Peak
Pr
(ppm)Peak
Ce
(ppm)Peak
La
(ppm)Width
≥1%
TREOWidth
≥0.1%
TREOPeak
Cu
(ppm)Peak
Co
(ppm)Peak
Ag
(g/t)C27 Skarn1.49% TREO1,1954385,8504,8702m45m26003205.1C26 Skarn0.46% TREO4731541,7771,270-18m4073-1.0TREO = Total Rare Earth Oxide; Nd = Neodymium; Pr = Praseodymium

Note: All reported intervals are downhole lengths; true widths have not yet been determined. TREO values are reported as oxide equivalents. Peak Nd and Pr values are from the highest-grade TREO intercepts within each anomaly. All values from certified laboratory analysis (ALS/Actlabs ME-MS81, ME-ICP61). Peak values represent maximum single-meter assay results. All rare earth elements, cobalt, copper, and silver are US DOI Critical Minerals (2025). Assay data is located on the Company's website at Tsodilo Resources Ltd. - Metals.

Geological Setting

The skarn deposits occur within carbonate-rich lithologies (marbles) and schists beneath 20 - 50 meters of Kalahari sediments cover. The REE mineralization is developed within endo-skarn formed along carbonate-rich marble lithologies, with bulk skarn mineralogy comprising pyroxene skarn (hedenbergite) and garnet skarn (andradite). REE minerals identified include carbonates (bastnäsite, ancylite), silicates (allanite, britholite), and phosphates (monazite, xenotime). This mineralogical assemblage is characteristic of skarn-hosted REE deposits globally and represents well-established REE mineral types with proven extraction methods.

The intercept grades at Gcwihaba fall within the range of reported grades for skarn-hosted REE deposits, which typically range from 0.02% to 3% TREO (Paulick and Machacek, 2017). The 1.49% TREO intercept at C27 represents the highest grade recorded at the project to date.

Exploration Implications

The high-grade intersections at C27 and broad mineralized intervals at C26 validate the Company's geophysical exploration approach using integrated magnetic and gravity surveys beneath Kalahari cover. The results support the conceptual exploration target of 81 to 97 million tonnes, which was generated through ground magnetics data inversion modeling, constrained by drilling results and geological interpretation. This approach provides a framework for systematic resource definition drilling campaign.

The 2026 drilling program will focus on defining high-grade zones exceeding 1% TREO, improving geological confidence, and collecting samples for metallurgical testwork. The planned 2026 drilling campaign comprises approximately 50 NQ-size drill holes totaling 15,000 meters, designed to support preparation of an initial mineral resource statement.

Quality Assurance / Quality Control (QAQC)

All diamond drill core from the Gcwihaba Metals Project was logged, photographed, and sawn in half using a diamond blade core saw. One half of the core was submitted for geochemical analysis, while the other half was retained in secure storage for reference. Sampling intervals were determined based on geological boundaries and typically ranged one meter. Control samples comprised approximately 10% of all samples submitted, including certified reference standards, analytical blanks, field duplicates, and preparation duplicates. QA/QC results were reviewed in real time, and all data have been verified as meeting acceptable thresholds for accuracy, precision, and contamination before inclusion in this release.

Diamond drill core samples were submitted for multi-element geochemical analysis at ALS Minerals Division, South Africa. Sample preparation comprised fine crushing to 70% passing 2mm (CRU-31), riffle splitting (SPL-21), and pulverizing to 85% passing 75 μm (PUL-31). Samples were analyzed using 38-element fusion inductively coupled plasma mass spectrometry (ICP-MS; method ME-MS81) for rare earth elements and yttrium, and 33-element four-acid digestion inductively coupled plasma atomic emission spectroscopy (ICP-AES; method ME-ICP61) for base and trace metals. Selected samples were also analyzed for precious metals using fire assay fusion ICP (method PGM-ICP23).

About Rare Earth Elements

The rare earths are an abundant group of seventeen elements composed of scandium, yttrium, and the lanthanides. The elements range in crustal abundance from cerium, the 25th most abundant element of the seventy-eight common elements in the earth's crust at 60 parts per million, to thulium and lutetium, the least abundant rare-earth elements at about 0.5 part per million. The elemental forms of rare earths are iron gray to silvery lustrous metals that are typically soft, malleable, and ductile and usually reactive, especially at elevated temperatures or when finely divided.

The rare earths' unique properties are used in a wide variety of applications. (Source: USGS National Minerals Information Center). NdFeB magnets are the most widely used, driving demand for four key REEs: Neodymium and Praseodymium as core inputs, and Dysprosium and Terbium" as essential additives for thermal stability. (Source: African Development Bank, Critical Mineral Insights 9 - Rare Earth Elements, November 24, 2025). In 2024, the U.S. imported 80% of the rare earth elements it used." (Source: USGS News Release, Interior Department releases final 2025 List of Critical Minerals, November 14, 2025)

Cautionary Note

The conceptual exploration target of 81 to 97 million tonnes for the C26 and C27 skarn anomalies was generated through magnetic and gravity geophysical modelling techniques using a ground magnetics inversion model, constrained by drilling results and geological interpretation. This modelling was completed in-house using Paradigm GOCAD software. The potential quantity and grade of this exploration target is conceptual in nature. There has been insufficient exploration to define a Mineral Resource in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects ("NI 43-101"), and it is uncertain if further exploration will result in the exploration target being delineated as a Mineral Resource. The exploration target should not be misconstrued as or considered equivalent to a Mineral Resource or Mineral Reserve.

QP Disclosure

Overall supervision of the Company's exploration program is the responsibility of Asele Maboshe, "Qualified Person" as such term is defined in National Instrument 43-101 ("NI 43-101"), who has reviewed and approved the technical information in this news release, and is not independent of the Company.

About Tsodilo Resources Limited

Tsodilo Resources Limited is an international mineral resource exploration company engaged in the search for economic metal deposits at its Gcwihaba Resources (Pty) Limited ("Gcwihaba") projects in Botswana. The Company has a 100% stake in its Gcwihaba project area consisting of five metal (base, precious, platinum group, and rare earth) prospecting licenses all located in the North-West district of Botswana.

This press release may contain forward-looking statements. All statements, other than statements of historical fact, which address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements pertaining to the use of proceeds, the impact of strategic partnerships and statements that describe the Company's future plans, objectives or goals) are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward- looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Factors that could cause actual results or events to differ materially from current expectations include, among other things, changes in equity markets, changes in general economic conditions, market volatility, political developments in Botswana and surrounding countries, changes to regulations affecting the Company's activities, uncertainties relating to the availability and costs of financing needed in the future, exploration and development risks, the uncertainties involved in interpreting exploration results and the other risks involved in the mineral exploration business. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not a guarantee of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and, even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations include, among other things, uncertainties relating to availability and cost of funds, timing and content of work programs, results of exploration activities, interpretation of drilling results and other geological data, risks relating to variations in the diamond grade and kimberlite lithologies; variations in rates of recovery and breakage; estimates of grade and quality of diamonds, variations in diamond valuations and future diamond prices; the state of world diamond markets, reliability of mineral property titles, changes to regulations affecting the Company's activities, delays in obtaining or failure to obtain required project approvals, operational and infrastructure risk and other risks involved in the diamond exploration and development business. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not a guarantee of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty. Neither the TSX Venture Exchange ("TSXV") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280123

Source: Tsodilo Resources Limited

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Nio stock price jumped by over 2% in Hong Kong, continuing a cautious recovery that started on Friday. It rose to a high of $38 after a proposal by the European Union that may help boost sales of Chinese EVs in the region. 

EU considers plan to replace tariffs on Chinese vehicles Copy link to section

Nio and other Chinese EV companies rose in Hong Kong and Beijing after a report suggested that EU officials were considering a minimum price system to replace import tariffs. Such a move would be highly positive for these companies as it would boost their sales and profit margins.

The plan will see Chinese vehicle companies submit their plans on their minimum import prices, annual volume limits, and future investments in the region. Such a move will remove the 35% tariff that these companies pay today.

Nio, a top Chinese manufacturer, would benefit from access to the European market, where it has attempted to gain market share over the years.

Europe is an ideal market because of its huge population of over 600 million people, who are much wealthier than those in other places. It would also help it to diversify its business from China, a country whose market has become highly saturated, with companies like Xiaomi, SAIC, XPeng, and Li Auto competing for market share.

Nio deliveries are doing well  Copy link to section

In a recent note, Nio said that its business was doing well, with demand for its vehicles continuing the uptrend. 

The company said that it delivered 48,135 vehicles in December, up by 54.6% from the same period a year earlier. It sold 124,807 vehicles in the fourth quarter, up by 71% YoY. This growth brought its annual deliveries to 326,028 vehicles, up by 47% YoY.

In contrast, Tesla delivered 418,227 vehicles in the fourth quarter, a 16% plunge from the same period in 2024. The company delivered over 97,000 vehicles in China in December.

Nio’s growth is being driven by ES-8, its sports utility vehicle (SUV), which has surpassed 40,000 deliveries, making it one of the fastest growing models in its category.

The most recent quarterly results showed that Nio made $3 billion in revenue in the third quarter while its gross margin jumped to 13.9% from the previous 10.9%.

Still, the main challenge that Nio faces is that its business has never been profitable, which has pushed it to raise money and dilute its shareholders. The company recently raised over $1.16 billion by selling American shares.

Nio stock price technical analysis  Copy link to section

Nio shares chart | Source: TradingView The daily timeframe chart shows that the Nio share price has been in a strong downward spiral in the past few months, moving from a high of $61.80 in October to the current $37.

It has formed a head-and-shoulders pattern, a common bearish reversal pattern, a common bearish reversal sign. 

The stock is about to form a death cross, which happens when the 50-day and 200-day Exponential Moving Averages (EMA). This pattern is one of the most bearish chart patterns in technical analysis.

Nio has also invalidated the double-bottom pattern at $37.80 and the neckline at $42.9. A double-bottom is one of the most common bullish reversal chart patterns.

The stock has now moved below the 61.8% Fibonacci Retracement level at $38.6. Moving below this level is important as most rebounds normally happen at this point.

Therefore, the most likely Nio share price forecast is bearish, with the next key support level to watch being at $32, the 78.7% Fibonacci Retracement level, which is 16% below the current level.

Exelixis, Inc. (EXEL) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 8:15 PM EST

Company Participants

Michael Morrissey - CEO, President & Director

Conference Call Participants

Matthew Bannon

Presentation

Matthew Bannon

All right. Welcome back to the 44th Annual JPMorgan Healthcare Conference. My name is Matt Bannon, and I'm a banker here at JPM. I am very pleased to be introducing our final presenting company of the day, Exelixis. And presenting on behalf of the company, we'll have President and CEO, Michael Morrissey.

Before I turn it over to Michael, I'll remind folks that this is a Q&A session. So please raise your hand if you have a question or ask it through the online portal, and I'll ask it on your behalf.

So without further ado, Michael?

Michael Morrissey
CEO, President & Director

All right. Fantastic. Thank you, and good evening, everybody. Thanks for hanging in there for one last session. I've been talking since 7:30 this morning. Meeting has been great, and I want to thank the JPMorgan team for the invitation and for the great, full packed schedule of one-on-one meetings. It's just a great day, great way to start the year. And we're excited to be able to tell you a little bit about Exelixis, where we've been in '25 and where we're going in 2026. So I'm going to follow my directions here with the pointer.

Okay. So before I begin, I'll be making forward-looking statements. So please see our SEC filings for a description of the risks that we face in our business, first. Second, we have -- we're going to be speaking to preliminary financial results and 2026 guidance today. Please note that the preliminary financial results were generated as of January 11 of this year, and we will have -- and are unaudited, and we'll have a full review of the final

Enovis Corporation (ENOV) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 7:30 PM EST

Company Participants

Damien McDonald - CEO & Director
Phillip Berry - Senior VP & CFO

Conference Call Participants

Robert Marcus - JPMorgan Chase & Co, Research Division

Presentation

Robert Marcus
JPMorgan Chase & Co, Research Division

Good afternoon, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Really happy to present our next speaker, Damien McDonald, CEO of Enovis; along with Ben Berry, the CFO. Damien and Ben are going to do a presentation, and I'll come up and we'll do some Q&A afterwards.

Gentlemen?

Damien McDonald
CEO & Director

Thanks, Robbie. Thanks for being here, everyone. My name is Damien. I'm the CEO. I've been with Enovis now for about 6 months. So I'm looking forward to some engaging questions. And Ben and I will do a little tag team, talk to you about the company. And then let's spend as much time as we can on Q&A, and be very interactive with us.

Standard forward-looking harbor -- safe harbor statement, so you can read that at your leisure.

Let's talk a little bit about Enovis. We're a orthopedics company, but orthopedics was a focus on mobility and the whole continuum of care. I'll come to that in a minute because it's been a journey as we've built this company over the last sort of 5-ish years through a series of 20-plus acquisitions. We're around about $2 billion in revenue. We're growing around about 6%, plus or minus. We just raised our guidance on EBITDA and EPS this morning.

And if you think about the business, it's roughly 50-50 orthopedics implants and prevention and recovery, and it's roughly 50-50 international and U.S. And it's been a journey to build this, and we're looking forward to telling you

January 13, 2026 01:00 ET  | Source: argenx SE

January 13, 2026, 7:00 AM CET 

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART® (IV: efgartigimod alfa-fcab) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). The application has been granted a Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026.

“Patients living with seronegative gMG continue to face limited treatment options and there remains a significant need to meaningfully improve their lives. The FDA’s acceptance of our sBLA with Priority Review status reflects the potential of VYVGART to address this need,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer, argenx. “This development brings us closer to expanding the use of VYVGART in a broad spectrum of patients with myasthenia gravis. We look forward to continuing our dialogue with the FDA as they review our application.”

The sBLA is supported by data from the Phase 3 ADAPT SERON study, which evaluated the efficacy and safety of VYVGART in adults with AChR-Ab seronegative gMG across all three subtypes – MuSK+, LRP4+, and triple seronegative gMG. The study met its primary endpoint (p-value=0.0068), demonstrating a statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score compared to placebo after four weeks.

In the overall population, mean change from baseline in patients treated with VYVGART was a clinically meaningful 3.35 point improvement in MG-ADL total score at week 4. Improvements in MG-ADL and Quantitative Myasthenia Gravis (QMG) scores were observed across subsequent treatment cycles in the overall population and in all patient subgroups, including MuSK+, LRP4+, and triple seronegative gMG.

VYVGART was well-tolerated with a safety profile consistent with the established profile of VYVGART in patients with AChR-Ab seropositive gMG and other indications. No new safety concerns were identified.

ADAPT SERON Study Design
The Phase 3 ADAPT SERON study is a randomized, double-blind, placebo-controlled, multi-center study evaluating the safety and efficacy of efgartigimod in adults with AChR-Ab seronegative gMG (n=119) across North America, Europe, China, and the Middle East. Part A randomized participants (1:1) received 4 once-weekly infusions of efgartigimod IV or placebo, followed by a 5-week follow-up and primary analysis. Part B is an open-label extension: participants receive 2 fixed cycles of 4 once-weekly efgartigimod infusions (4-week interval between cycles); from cycle 3 onward, additional cycles could be started ≥1 week after the last administration of the previous cycle, based on clinical status. The primary endpoint is the MG-ADL total score change from baseline to day 29 in part A. Other scales of evaluation include QMG, MG-QoL 15r, MGC, and EQ-5D-5L VAS. Enrolled participants had a confirmed MG diagnosis by an independent panel of experts, and an MG-ADL total score of 5 or greater. Participants were on a stable dose of at least one gMG treatment prior to randomization, including acetylcholinesterase inhibitors, corticosteroids or nonsteroidal immunosuppressive drugs. Participants were eligible to enroll in ADAPT SERON if they were AChR-Ab seronegative, which included participants who are MuSK-Ab seropositive, LRP4-Ab seropositive, or triple seronegative.

MG-ADL is a validated measure of disease activity in patients living with myasthenia gravis, which evaluates the functional impact of symptoms on daily activities such as speaking, chewing, swallowing, breathing, and limb strength.

About AChR-Ab Seronegative Generalized Myasthenia Gravis (gMG)
Generalized myasthenia gravis (gMG) is a rare, chronic, neuromuscular autoimmune disease caused by pathogenic IgGs targeting the neuromuscular junction (NMJ), resulting in impaired neuromuscular transmission and debilitating and potentially life-threatening muscle weakness and chronic fatigue. Approximately 80% of patients with gMG have detectable antibodies against the AChR in sera, and these patients are diagnosed as AChR-Ab seropositive gMG. Approximately 20% of patients with gMG do not have detectable serum antibodies directed against AChR and are referred to as AChR-Ab seronegative gMG. These patients may have detectable autoantibodies targeting other NMJ proteins, such as muscle-specific tyrosine kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4), or others. Anti-MuSK antibodies are detected in approximately 1-10% of patients with gMG, while anti-LRP4 antibodies are detected in approximately 1-5% of patients with gMG. About 10% of patients do not have any detectable autoantibodies against AChR, MuSK or LRP4. These triple seronegative patients have historically been excluded from studies and have a higher disease burden and unmet medical need compared to patients with detectable autoantibodies. Currently, there are no approved treatments available for patients with anti-LRP4 antibodies or for triple seronegative patients.

Important Safety Information 

What is VYVGART® (efgartigimod alfa-fcab)? 
VYVGART is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

 IMPORTANT SAFETY INFORMATION 
Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. VYVGART can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

 VYVGART may cause serious side effects, including: 

Infection. VYVGART may increase the risk of infection. The most common infections were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain. Allergic Reactions (hypersensitivity reactions). VYVGART can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with VYVGART.  Infusion-Related Reactions. VYVGART can cause infusion-related reactions. The most frequent symptoms and signs reported with VYVGART were high blood pressure, chills, shivering, and chest, abdominal, and back pain.   Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

 Before taking VYVGART, tell your doctor if you: 

take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have received or are scheduled to receive a vaccine (immunization), or have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.  What are the common side effects of VYVGART? 
The most common side effects of VYVGART are respiratory tract infection, headache, and urinary tract infection.

These are not all the possible side effects of VYVGART. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088. 

Please see the full Prescribing Information for VYVGART and talk to your doctor. 

About VYVGART
VYVGART is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. It is the first approved FcRn blocker in the United States, EU, China and Canada for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and in Japan for the treatment of adults with gMG who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).

Media:
Colin McBean
[email protected]

Investors:
Alexandra Roy
[email protected]

FORWARD LOOKING STATEMENTS
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “commit,” and “continue,” and include statements argenx makes concerning the potential of VYVGART to meaningfully improve the lives of seronegative gMG patients who continue to face limited treatment options; its goal to expand the use of VYVGART in a broad spectrum of patients with myasthenia gravis; its commitment to improve the lives of people suffering from severe autoimmune diseases; and its aim to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article is exclusive to Seeking Alpha. No duplication or reproduction of this article is allowed without consent of Seeking Alpha and the author. This article should not be misconstrued as individual financial advice. Always conduct your own due diligence prior to investing.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

CorMedix Inc. (CRMD) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 7:30 PM EST

Company Participants

Joseph Todisco - CEO & Chairman of the Board of Directors

Presentation

Unknown Attendee

Hi, all, and welcome to the session. My name is Arvind, and I'm an associate at JPMorgan. I'm excited today to introduce CorMedix. With us today, we have Joe Todisco, Chairman and CEO. And just a reminder on format, we'll have a 20-minute presentation followed by 20 minutes of Q&A. So please hold all your questions until the end. Thank you.

Joseph Todisco
CEO & Chairman of the Board of Directors

Thank you, Arvind. I know it's late in the day, so I appreciate such a packed room for this time of day, and I know it's been long, so I'll try and keep it succinct. I am Joe Todisco, I'm the Chairman and CEO of CorMedix, and welcome to CorMedix 2026 JPMorgan presentation. A quick look at our forward-looking statements, which you can find in more detail in our SEC filings.

I'll start by talking a little bit about who is CorMedix Therapeutics. So CorMedix Therapeutics is a diversified specialty pharmaceutical company with a portfolio of commercial and pipeline drugs predominantly focused on institutional settings of care, and that would be products that are utilized in hospitals, infusion centers, mostly injectable drugs. We have an attractive financial profile. We have about $150 million cash on hand, close to 0 net debt. Our revenue guidance for 2026 is over $300 million in revenue and $100 million to $125 million of EBITDA. But most importantly, from a cash position, we expect to add to cash throughout the year.

We are a scalable platform, right? We've got a solid commercial team with experience across multiple therapeutic areas on which we can onboard

IDEAYA Biosciences, Inc. (IDYA) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 6:45 PM EST

Company Participants

Yujiro Hata - Founder, President, CEO & Director
Stuart Dorman - Chief Commercial Officer
Darrin M. Beaupre - Chief Medical Officer

Conference Call Participants

Anupam Rama - JPMorgan Chase & Co, Research Division

Presentation

Anupam Rama
JPMorgan Chase & Co, Research Division

Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Priyanka Grover, [ Joyce Sau ] and [ Roti Pinhe ]. Our next presenting company is IDEAYA, and presenting on behalf of the company, we have CEO, Yujiro Hata.

Yujiro Hata
Founder, President, CEO & Director

Well, thank you, upon for the introduction. And thank you again to JPMorgan for allowing us to present at the 44th Annual Healthcare Conference at JPMorgan.

Please note, we'll be making forward-looking statements today and please refer to our SEC filings as appropriate.

Since IDEAYA's founding 10 years ago, we've had several strategic guideposts that have led our organization, including first-in-class targets, predictive biomarkers, rational combinations and early-stage disease. Those strategic focus areas has led us today to have 4 clinical pipeline focus areas that we'll cover during today's presentation.

The first is darovasertib. This program is now in a registrational study and we are guiding towards top line results this quarter to enable our potential first accelerated approval filing in the United States. We believe darovasertib is truly a unique molecule and has the opportunity to potentially define this indication in uveal melanoma across both the neoadjuvant, adjuvant and metastatic settings.

Next is our focus in the area of ADCs and DNA damage repair. For many of you that have known us for the last 10

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

LONDON--(BUSINESS WIRE)--Hunting PLC (LSE: HTG), the global precision engineering group, today announces its 2025 Full Year Trading Statement for the 12 months ended 31 December 2025, ahead of the Group's audited full year results, which are due to be published on Thursday 5 March 2026. 2025 Summary Financials (unaudited) Group EBITDA of c.$135 million, up 7% year-on-year. Group EBITDA margin of c.13% recorded, up from 12% in prior year. c.$350 million sales order book at year-end, reflecting c.

Calgary, Alberta and Houston, Texas--(Newsfile Corp. - January 13, 2026) - PetroTal Corp. (TSX: TAL) (AIM: PTAL) (OTCQX: PTALF) ("PetroTal" or the "Company") is pleased to provide the following operational and financial updates. All amounts are in US dollars unless stated otherwise.

Please see below information about transactions made under the fourth tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Date on which the buy-back tranche was announced: 29 October 2025.

The duration of the buy-back tranche: 30 October 2025 to no later than 2 February 2026.

Further information on the tranche can be found in the stock market announcement on its commencement dated 29 October 2025, available here: https://newsweb.oslobors.no/message/658157

From 5 January to 9 January 2026, Equinor ASA has purchased a total of 1,489,502 own shares at an average price of NOK 236.9155 per share.

Overview of transactions:

DateTrading venueAggregated daily volume (number of shares)Daily weighted average share price (NOK)Total daily transaction value (NOK)     5 JanuaryOSE293,501240.969170,724,671.82 CEUX    TQEX        6 JanuaryOSE290,500241.441070,138,610.50 CEUX    TQEX        7 JanuaryOSE304,000231.663770,425,764.80 CEUX    TQEX        8 JanuaryOSE304,501232.343670,748,858.54 CEUX    TQEX        9 JanuaryOSE297,000238.545970,848,132.30 CEUX    TQEX        Total for the periodOSE1,489,502236.9155352,886,037.96 CEUX    TQEX        Previously disclosed buy-backs under the trancheOSE12,474,239237.04322,956,932,978.54CEUX   TQEX   Total12,474,239237.04322,956,932,978.54     Total buy-backs under the tranche (accumulated)OSE13,963,741237.02953,309,819,016.50CEUX   TQEX   Total13,963,741237.02953,309,819,016.50 Following completion of the above transactions, Equinor ASA owns a total of 58,321,934 own shares, corresponding to 2.28% of Equinor ASA’s share capital, including shares under Equinor’s share savings programme (excluding shares under Equinor’s share savings programme, Equinor owns a total of 47,286,051 own shares, corresponding to 1.85% of the share capital).

This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Appendix: A overview of all transactions made under the buy-back tranche that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

Contact details:

Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791

Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584

Detailed overview of transactions

Story (IP) Price Rebounds 100%, but On-Chain Data Tells a Different StoryStory IP price doubled but onchain data shows weak network growth today.Korean traders drove volume with Upbit dominating most IP volume.Speculation outweighs adoption as active users stay low despite strong price recovery.Story (IP) is a Layer-1 blockchain designed specifically to bring intellectual property (IP) on-chain and turn it into programmable assets. In early 2026, the IP token staged a strong recovery. The price doubled from a local low near $1.50 to above $3.00.

What is driving this rebound? And is it strong enough to continue in the coming months?

Sponsored

Korean Traders Push IP HigherTrading data indicate that South Korean traders contributed the most to IP’s recent price surge.

CoinGecko data shows that IP’s daily trading volume exceeded $300 million on January 13. This was the highest level since the sell-off in October last year, when IP dropped more than 80% in a single day.

IP trading volume on exchanges. Source: CoinGeckoUpbit alone accounted for more than 47% of total trading volume. Upbit is one of South Korea’s largest crypto exchanges. This highlights that Korean traders were the main force behind IP’s rally.

On Upbit, the IP/KRW pair also represented more than 12% of total trading activity. It ranked second only to XRP/KRW.

Sponsored

However, Upbit’s dominance suggests that the price increase came mainly from regional demand rather than global adoption.

Some analysts also believe that whales played a role in driving this rally.

“Story Protocol has had the biggest rise this week. With a price increase of over 30%, IP has rallied due to a narrative revival. Massive trading volume came in as new investors and whales joined the project,” Investor Sjuul | AltCryptoGems said.

Sponsored

IP User Data Shows No BreakoutDespite the price surge, on-chain data tells a different story. The rally lacks strong fundamental support.

Data from Storyscan indicates that the number of active accounts on the Story network has remained relatively unchanged in recent months.

Daily Active Account on Story (IP). Source: StoryscanThe figure fell from more than 10,000 last year to fewer than 500 today. This represents a decline of about 95%. The number of daily new users on the Layer-1 network has also remained almost flat. The number stays below 100 per day. It is far lower than the average of more than 2,000 per day seen in August and September last year.

Sponsored

Daily New Account on Story (IP). Source: StoryscanThese figures suggest that the rally is primarily driven by speculation and increased trading volume. It does not reflect real network growth, such as more tokenized IP or stronger real-world usage.

Meanwhile, technical analysts are warning about downside risks. On the daily timeframe, IP is approaching a key resistance zone between $3.00 and $3.30.

“On the daily timeframe, IP is moving up with strong candles and solid indicators. However, the price is now close to the $3.0–$3.3 resistance zone. A breakout could confirm a change of character and start a bullish trend. Wait for confirmation and do not rush,” CryptoPulse commented.

Despite the recent doubling in price and the surge in volume, IP remains down about 80% from its $15 peak last year. The long-term growth of this altcoin will depend on real user adoption and demand for decentralized IP management.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Breaking News

Skip to the content Home Altcoins News Story Protocol Sees 100% Price Rise, On-Chain Data Shows Limited Growth

Steven Anderson January 13, 2026

The Story Protocol, a Layer-1 blockchain, experienced a significant price increase in early 2026, with its IP token doubling in value from approximately $1.50 to over $3.00. This surge was largely attributed to the activities of South Korean traders. According to CoinGecko, on January 13, the daily trading volume of IP surpassed $300 million, marking the highest since a sharp decline in October of the previous year.

A notable portion of this trading activity was concentrated on Upbit, a major South Korean cryptocurrency exchange, which accounted for more than 47% of the volume. The IP/KRW trading pair was particularly active, representing over 12% of Upbit’s total trading activity, second only to the XRP/KRW pair. This concentration on a single regional exchange suggests the price increase was driven by local demand rather than a broader international interest.

Some market analysts have speculated that the rally also involved significant participation from large investors, often referred to as ‘whales.’ Investor Sjuul from AltCryptoGems noted that the price increase was propelled by renewed interest and narrative around the project, attracting both new investors and whales.

Despite the price rebound, on-chain metrics from Storyscan indicate a lack of corresponding network growth. The number of active accounts on the Story network has seen a sharp decline, from over 10,000 in the previous year to fewer than 500. Similarly, the daily creation of new accounts has remained below 100, a substantial drop from the average of over 2,000 per day recorded in August and September of the prior year. This suggests that the recent price rally may be more speculative, lacking substantial growth in the network’s user base or real-world applications.

Technical analysts have highlighted potential risks, noting that the IP token is nearing a critical resistance zone between $3.00 and $3.30. CryptoPulse commented that while the token shows positive indicators, confirmation is needed before predicting a sustained bullish trend.

Despite the recent doubling in price, the IP token’s value remains approximately 80% below its peak of $15 from the previous year. The long-term prospects for the token will depend on the actual adoption of decentralized intellectual property management and genuine user engagement with the network. The market will be closely watching for any shifts in trading patterns or new developments that could influence the token’s future trajectory.

Post Views: 12

Steven Anderson Steven is an explorer by heart – both in the physical and the digital realm. A traveler, Steven continues to visit new places throughout the year in the physical world, while in the digital realm has been instrumental in a number of Kickstarter projects. Technology attracts Steven and through his business acumen has gained financial profits as well as fame in his business niche. Send a tip to: 0x75395Ea9a42d2742E8d0C798068DeF3590C5Faa5

Crypto newsletter Get the latest Crypto & Blockchain News in your inbox.

After a brief rebound, crypto bulls have hit the brakes. Most top tokens are trading flat, with Bitcoin price holding its recent gains and Ethereum price staying firm above $3,100, signaling steady demand. Now, the market is heading into a three-day catalyst cluster that could trigger sharp, headline-driven swings. Key U.S. events line up back-to-back this week—the CPI inflation print, Senate consideration of the CLARITY Act, and a Supreme Court ruling tied to U.S. tariffs—all capable of flipping risk sentiment in minutes.

Adding to the tension, President Trump has floated a fresh tariff regime, reviving chatter of a potential “tariff war.” With BTC and ETH consolidating near key levels, traders are watching one question closely: do these headlines spark a risk-off flush that cracks support, or do majors absorb the volatility and hold their ground?

Jan 13: U.S. Inflation Reading (CPI) The U.S. Bureau of Labour Statistics has CPI scheduled for Tuesday, Jan 13, 2026. This data point matters because it directly shapes how markets price the path of U.S. monetary policy—and that pricing flows through to yields, the dollar (DXY), and risk assets. 

How crypto typically reacts:

Hotter-than-expected CPI: yields tend to jump, the dollar firms, and risk assets often sell first. BTC can drop quickly as leverage unwinds.Softer CPI: yields often cool, the dollar eases, and BTC tends to catch a bid as risk sentiment improves.This doesn’t mean CPI “decides” the trend. It often decides the week’s volatility regime, whether markets punish leverage or reward it.

Jan 14: Supreme Court Rulings on Trump’s TariffsThe Supreme Court is scheduled to issue rulings on January 14, and reporting indicates tariff-related issues are among what markets are watching. 

Tariff rulings and tariff headlines can shift “risk-on/risk-off.” When markets start pricing slower growth, retaliation, or trade disruption, liquidity often moves into the dollar and away from high-beta assets—crypto included.

Think of it as a sentiment accelerant: it can amplify whatever CPI sets in motion.

Jan 15: CLARITY Act in the SenateThe Digital Asset Market Clarity Act (H.R.3633) is a major U.S. crypto market structure bill, and it’s on the Hill’s radar this week. The bill text and status are on Congress.gov, and at minimum, it keeps regulatory clarity in the headlines. 

Why traders care:

Positive momentum headlines can lift sentiment for majors and U.S.-exposed tokens.Contentious revisions, delays, or political pushback can do the opposite.Even without final passage, this can drive a narrative bid or narrative fade, especially if macro is already volatile.

The Core Risk: Trump’s 25% Tariff Threat  AS per the recent reports, Trump said any country doing business with Iran would face a 25% tariff on trade with the U.S. The report specifically pointed to countries with Iran trade ties, such as China, the UAE, and India. The headline is big, but details on scope and authority were not clearly laid out at the time. 

Will there be a tariff war again?

It’s plausible, but not automatic. The markets may trade the fear before they trade the policy, which may kick off the volatility of the markets. As seen in previous times, the markets plunged significantly and remained under bearish influence for a while. However, the markets recovered then and may also recover, pushing the bullish rally for some time. 

Impact on Bitcoin and AltcoinsBitcoin price has already begun to consolidate within a tight range as the traders are keeping a close watch on the upcoming events. In the first reaction window, BTC often trades like a high-liquidity risk asset. If CPI is hot or tariff fear spikes, BTC can see fast downside wicks as leverage gets flushed. On the other hand, if CPI is soft and tariff headlines de-escalate, BTC usually rebounds first and drags majors with it.

BTC can sometimes benefit later from “uncertainty” narratives, but that tends to show up after the initial liquidation phase, not during it. Secondly, Altcoins typically overreact in both directions. They dive deeper if the BTC price plunges and also display sharper bounces otherwise, but tend to be more fragile. 

What Traders Can Expect This WeekExpect fast, headline-driven volatility rather than a clean trend. CPI can move yields and the dollar within minutes, the tariff ruling can swing risk sentiment mid-session, and CLARITY Act headlines can trigger sudden pumps or fades in majors and U.S.-linked tokens. That means BTC and ETH may show sharp wicks on both sides before choosing direction, while alts likely amplify the move either way.

For traders, this week demands execution over prediction: reduce position size, avoid heavy leverage into event windows, and trade confirmed breaks instead of first reactions. Keep invalidation levels tight, watch DXY and U.S. yields alongside BTC, and be ready for a “tariff war” headline to flip the tape quickly. If support holds through the news cycle, upside continuation stays on the table, but if they crack, the market can turn risk-off in a hurry.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

A bizarre on-chain event has sparked confusion across the XRP community today.

In a span of just 62 minutes, a massive stash of 73 million XRP was transferred between five different anonymous wallets. 

The entire sum was valued at $151.3 million at the time of the transfer. 

The on-chain “hot potato”XRP researcher Leonidas Hadjiloizou has jokingly commented that nobody wants this massive number of tokens. 

The fact that the entire lump sum is kept intact indicates that this is a security protocol or liquidity routing by a single large entity. This is likely an exchange or custodian. 

XRP is currently changing hands at $2.07. 

Bitwise chief investment officer Matt Hougan has slammed the idea that Bitcoin shouldn’t be used for investment and 401(k)s because of its volatility — arguing that some stocks are also prone to even larger price swings.

Hougan made the comments on the same day US Senator Elizabeth Warren pressed the US Securities and Exchange Commission (SEC) for answers on how it would mitigate risks involved in allowing crypto in retirement funds. 

In August last year, US President Donald Trump signed an executive order directing the Labor Department to reevaluate restrictions around alternative assets in defined-contribution plans, opening the door for cryptocurrencies to be included in 401(k) retirement plans.

During an interview with Investopedia Express Live on Monday, Hougan called previous attempts to block Bitcoin (BTC) investment by management companies like Vanguard and regulators' advice against inclusion in 401(k)s “ridiculous.”

“This is just another asset. Does it go up and down? Absolutely. Is there risk in it? Absolutely. But it's actually less volatile over the last year than Nvidia stock, and you don't see any rules about banning 401(k) providers from offering Nvidia stock,” he said.

Bitwise chief investment officer Matt Hougan says Bitcoin can be less volatile than some stocks, and bans on investing in it are ridiculous. Source: YouTube Shares in US tech giant Nvidia hit a yearly low of roughly $94.31 in April 2025, before spiking to a high of over $207 by October, representing a price swing of 120%. 

On the other hand, Bitcoin fluctuated between a low of $76,000 in April and a high of $126,080 in October, amounting to a 65% swing between the two.

Crypto in 401(k)s has been a long-sought-after opportunity for crypto firms aiming to reach more retail investors and achieve greater financial system legitimacy.

Warren demands SEC answers on crypto in 401(k)Meanwhile, US Senator Elizabeth Warren is demanding answers from the SEC about how it will mitigate any risks for 401(k) plans that choose to invest in “alternative investments,” like crypto.

In an open letter published on Monday, Warren argued that crypto in retirement plans might not lead to better outcomes for participants due to higher fees and expenses “that typically come with them,” along with crypto’s volatility.

“For most Americans, their 401(k) represents a lifeline to retirement security rather than a playground for financial risk. Allowing crypto into American retirement accounts creates fertile ground for workers and families to lose big,” she added.

Warren has demanded that SEC Chair Paul Atkins answer whether the regulator is taking into account volatility when valuing crypto holdings for publicly traded companies no later than Jan. 27.

She also wants to know if the SEC has assessed the use of manipulative practices in crypto markets and if the regulator will publish research and other educational materials to help raise investor awareness.

Crypto in 401(k)s will be normalized, eventuallyOutside of Trump's executive order, in May, the Department of Labor’s Employee Benefits Security Administration announced a “neutral stance, neither endorsing nor disapproving,” of crypto in 401(k)s after rescinding a compliance release from 2022 that had previously discouraged the practice.

Hougan said it’s unclear if 401(k) providers will start to invest in crypto during 2026, but predicts it will eventually happen and become normalized.

“These are very slow-moving institutions, but we're moving in that direction, and eventually it'll be normalized like other assets, which is how it should be,” he added.

Magazine: How crypto laws changed in 2025 — and how they’ll change in 2026

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy